Get the Stockscreener App
0.7501
2.05%
0.0151
After Hours:
.75
-0.000100
-0.01%
Avenue Therapeutics Inc stock is traded at $0.7501, with a volume of 294.
It is up +2.05% in the last 24 hours and up +2.05% over the past month.
See More
Previous Close:
$0.735
Open:
$0.773883
24h Volume:
294
Relative Volume:
0.55
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.1969
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
+2.05%
1M Performance:
+2.05%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.7501
$0.7739
1-Week Range:
$0.7501
$0.7739
52-Week Range:
$0.5231
$0.7739
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.7501 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN
Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma
Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail
Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo
Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria
Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa
Axsome Therapeutics stock hits all-time high at 139.22 USD - Investing.com India
Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus
AZN Secures Deal with Axsome for Epilepsy Drug Development - GuruFocus
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com South Africa
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - The Manila Times
OTC Markets Group Welcomes SUN SILVER LTD. to OTCQX - The Manila Times
Global Pain Management Devices Market Set to Expand Rapidly at a CAGR of ~8% by 2032 Amid Growing Preference for Minimally Invasive Solutions | DelveInsight - Business Upturn
Nebius Group NV Leads Six-Month Stock Performance with 374.29% Return - Markets Mojo
OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan
Can Dianthus Therapeutics Inc. stock attract ESG capital inflowsPortfolio Value Summary & AI Driven Price Forecasts - fcp.pa.gov.br
Lirum Therapeutics Announces FDA 'Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor - The Manila Times
Lirum Therapeutics Announces FDA “Study May Proceed” Letter - GlobeNewswire
Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times
Denali Therapeutics (NASDAQ:DNLI) versus PureTech Health (NASDAQ:PRTC) Critical Comparison - Defense World
Xtrackers MSCI Kokusai Equity ETF (NYSEARCA:KOKU) Trading 1.4% Higher – Still a Buy? - Defense World
Nexus Industrial REIT (OTCMKTS:EFRTF) Shares Down 2.5% – Should You Sell? - Defense World
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - The Manila Times
Apogee Therapeutics, Inc. Announces Closing of Public - GlobeNewswire
Avenue Therapeutics, Inc. (ATXI) stock price, news, quote and history - Yahoo
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
United States Drug Resistant Epilepsy Market 2025 | Industry Developments, Future Growth, Share & Industry Insights - openPR.com
Speedy Hire (LON:SDY) Shares Up 18.8% Following Insider Buying Activity - Defense World
Operating cash flow per share of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Vital Farms, Inc. (VITL) Attracts New Investment from Park Avenue Securities - Yahoo Finance
Ceapro (OTCMKTS:CRPOF) and Avenue Therapeutics (NASDAQ:ATXI) Financial Contrast - Defense World
Affiliate of Pacific Avenue Capital Partners Completes the Acquisition of Pick Your Part from LKQ Corporation - Shreveport Times
Park Avenue Securities LLC Has $212,000 Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - Defense World
Corcept Therapeutics (NASDAQ:CORT) and EOM Pharmaceutical (OTCMKTS:IMUC) Head-To-Head Contrast - Defense World
United Therapeutics Corporation $UTHR Stake Lifted by Park Avenue Securities LLC - Defense World
2,085 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Has $622,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - Defense World
Novo Nordisk A/S (NVO) Attracts Park Avenue Securities Investment - Yahoo Finance
Postoperative Pain Management Market to Expand Significantly by 2032, States DelveInsight Report - openPR.com
Third Avenue Value Fund's Strategic Moves: Conduit Holdings Ltd Takes Center Stage - Yahoo Finance
SpringWorks Therapeutics Inc.’s volatility index tracking explainedEarnings Overview Summary & Stock Portfolio Risk Management - newser.com
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Profit Summary & AI Optimized Trade Strategies - newser.com
Is TScan Therapeutics Inc. meeting your algorithmic filter criteria2025 Valuation Update & Safe Capital Growth Tips - newser.com
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol - IT Business Net
7 Biotech Stocks Trading At 52-Week HighsCan The Rally Continue? - RTTNews
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Nasdaq Compliance and Long-Term Viability of Society Pass (SOPA) - AInvest
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Dietary Changes Could Provide a Therapeutic Avenue for Brain Cancer | Newswise - Newswise
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Cap:
|
Volume (24h):